Christopher John Helal

This inventor holds 33 USPTO granted patents and 9 published patent applications, plus 11 CIPO patents and 19 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Pfizer Corporation, Ge Healthcare Limited. Active years: 2008-2025.

USPTO Granted Patents = 33 (Patent Applications = 9)

% Patents Active = 57.6

CIPO Patents = 11 (Patent Applications = 10)

EPO Patents = 19 (Patent Applications = 24)

Average Co-Inventor Count = 5.8

ph-index = 4

Forward Citations = 99(Granted Patents)

Location History:

East Lyme, CT (US) (2008 - 2012)
Mystic, CT (US) (2013 - 2024)

Company Filing History:

Ge Healthcare Limited

patents

Years Active: 2008-2025

Loading Chart...

Areas of Expertise:

MAGL Inhibitors

Tricyclic Compounds

LRRK2 Inhibitors

Amino-Heterocyclic Compounds

Imidazo[4,5-C]quinoline Derivatives

Pyrazolopyrimidine Compounds

Triazine Derivatives

Heteroaromatic Quinoline Compounds

Piperazine Derivatives

Imidazopyridazine Compounds

Benzyl-Lactam Derivatives

Cyclic Substituted Compounds

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12398119 - Piperazine azaspiro derivatives (2025-08-26),

2. 12049465 - Tricyclic compounds and their use as phosphodiesterase inhibitors (2024-07-30),

3. 11524954 - Piperazine azaspiro derivatives (2022-12-13),

4. 11472805 - Tricyclic compounds and their use as phosphodiesterase inhibitors (2022-10-18),

5. 11312713 - Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors (2022-04-26),

6. 11161844 - Cyclic substituted imidazo[4,5-c]quinoline derivatives (2021-11-02),

7. 10858373 - Heterocyclic spiro compounds as MAGL inhibitors (2020-12-08),

8. 10738063 - 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds (2020-08-11),

9. 10723711 - 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors (2020-07-28),

10. 10669279 - Imidazopyridazine compounds (2020-06-02),

11. 10626125 - 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors (2020-04-21),

12. 10428034 - 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors (2019-10-01),

13. 10329308 - 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors (2019-06-25),

14. 10323042 - 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds (2019-06-18),

15. 10131669 - Pyrazolopyrimidine compounds (2018-11-20),

Title: The Inventive Mind of Christopher John Helal

Introduction:

Christopher John Helal, a prolific inventor hailing from Mystic, CT (US), has made significant contributions to the field of pharmaceuticals through his innovative patents. With a total of 31 patents, his work has had a profound impact on the treatment of various disorders.

Latest Patents:

Two of Helal's latest patents showcase his ingenuity and commitment to advancing medical science. The first patent involves Piperazine azaspiro derivatives, which have shown promise in treating M4-mediated disorders such as Alzheimer's Disease, Parkinson's Disease, and schizophrenia. The second patent focuses on tricyclic compounds as phosphodiesterase inhibitors, opening up new possibilities in pharmaceutical treatments.

Career Highlights:

Having worked at esteemed companies like Pfizer Corporation and GE Healthcare Limited, Helal's career is marked by a dedication to pushing boundaries and exploring new frontiers in pharmaceutical research. His patents stand as a testament to his expertise and passion for innovation in the medical field.

Collaborations:

Throughout his career, Helal has collaborated with talented individuals such as Patrick Robert Verhoest and Thomas Allen Chappie. These partnerships have resulted in groundbreaking inventions that have the potential to improve the lives of countless individuals facing various health challenges.

Conclusion:

Christopher John Helal's inventive spirit and unwavering commitment to scientific progress have solidified his position as a respected figure in the world of pharmaceutical innovations. His patents not only reflect his creativity but also underscore his desire to make a meaningful difference in the realm of healthcare. With a track record of success and a passion for discovery, Helal continues to inspire future generations of inventors to dream big and pursue groundbreaking ideas.